We are live on ! Find out more
REGN icon

Regeneron Pharmaceuticals
REGN

473 hedge funds and large institutions have $25.8B invested in Regeneron Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 141 increasing their positions, 203 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 33

21% more capital invested

Capital invested by funds: $21.3B → $25.8B (+$4.52B)

18% more funds holding in top 10

Funds holding in top 10: 11 → 13 (+2)

6% more funds holding

Funds holding: 447 → 473 (+26)

31% less repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 203

35% less call options, than puts

Call options by funds: $378M | Put options by funds: $580M

Holders
473
Holders Change
+26
Holders Change %
+5.82%
% of All Funds
13.73%
Holding in Top 10
13
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+18.18%
% of All Funds
0.38%
New
66
Increased
141
Reduced
203
Closed
33
Calls
$378M
Puts
$580M
Net Calls
-$202M
Net Calls Change
-$33M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$230M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$156M
3
BFA
BlackRock Fund Advisors
California
+$150M
4
Polen Capital Management
Polen Capital Management
Florida
+$115M
5
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$76.5M

Top Sellers

1
Viking Global Investors
Viking Global Investors
Connecticut
-$631M
2
Goldman Sachs
Goldman Sachs
New York
-$264M
3
Norges Bank
Norges Bank
Norway
-$209M
4
Artisan Partners
Artisan Partners
Wisconsin
-$112M
5
Franklin Resources
Franklin Resources
California
-$102M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital World Investors
1
Capital World Investors
California
$2.66B +$11.9M +35,641 +0.5%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$2.15B +$230M +686,906 +13%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$2.1B +$56M +166,994 +3%
Sands Capital Management
4
Sands Capital Management
Virginia
$1.79B +$20.1M +60,104 +1%
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.39B -$18.1M -54,150 -1%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$1.18B +$156M +465,361 +17%
State Street
7
State Street
Massachusetts
$1.13B -$30.4M -90,714 -3%
Artisan Partners
8
Artisan Partners
Wisconsin
$1.03B -$112M -333,253 -10%
BIT
9
BlackRock Institutional Trust
California
$723M -$30.9M -92,116 -4%
BFA
10
BlackRock Fund Advisors
California
$687M +$150M +448,225 +31%
JP Morgan Chase
11
JP Morgan Chase
New York
$557M -$45.8M -136,585 -8%
Wells Fargo
12
Wells Fargo
California
$533M -$58.2M -173,775 -11%
Invesco
13
Invesco
Georgia
$414M +$2.93M +8,748 +0.8%
UBS AM
14
UBS AM
Illinois
$396M -$12.8M -38,227 -3%
Viking Global Investors
15
Viking Global Investors
Connecticut
$390M -$631M -1,882,774 -64%
Northern Trust
16
Northern Trust
Illinois
$347M -$19.6M -58,548 -6%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$340M -$15.1M -44,945 -5%
BA
18
BlackRock Advisors
Delaware
$273M -$59.4M -177,228 -19%
Deutsche Bank
19
Deutsche Bank
Germany
$259M -$7.21M -21,508 -3%
Norges Bank
20
Norges Bank
Norway
$242M -$209M -622,423 -48%
BG
21
BlackRock Group
United Kingdom
$219M -$8.3M -24,762 -4%
Massachusetts Financial Services
22
Massachusetts Financial Services
Massachusetts
$204M +$8.58M +25,612 +5%
Polen Capital Management
23
Polen Capital Management
Florida
$199M +$115M +343,312 +165%
Bank of America
24
Bank of America
North Carolina
$199M -$36.4M -108,724 -16%
Franklin Resources
25
Franklin Resources
California
$196M -$102M -304,919 -36%
1
2 3 4 5

REGN Hedge Fund Activity: Q3 2014 in Review

473 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2014, worth a combined $25.8B — up 21% from $21.3B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new REGN positions and 33 closed out — a net gain of 33 holders — while 141 added to existing stakes and 203 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $230M. The largest seller was Viking Global Investors, cutting an estimated $631M.

  • 473 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2014, up from 447 in Q2 2014.
  • Funds reported $25.8B of Regeneron Pharmaceuticals stock for Q3 2014, up 21% quarter-over-quarter.
  • 66 funds opened new Regeneron Pharmaceuticals positions in Q3 2014 and 33 closed out, a net change of +33 holders.
  • The largest Regeneron Pharmaceuticals buyer in Q3 2014 was Fidelity Investments, an estimated $230M added.
  • The largest Regeneron Pharmaceuticals seller in Q3 2014 was Viking Global Investors, an estimated $631M sold.

Based on aggregated 13F filings for Q3 2014.